Technology / Software - Hybridoma cell lines secreting monoclonal antibodies (Ref. TEC0072)
Hybridomas are obtained by fusing normal B lymphocytes with a myeloma (tumor B cell line). Thus, a cloned hybridoma cell line has an unlimited capacity to grow in culture, producing immunoglobulin molecules with identical structure and antigen specificity, termed monoclonal antibodies (mAbs), which may have a wide variety of applications.
BACKGROUND
Monoclonal antibodies specific for molecules expressed by leukocytes, termed “leukocyte differentiation antigens” (CD) are used in biomedical research, as well as for the detection of biomarkers with diagnostic, prognostic and/or therapeutic interest in the clinical management of different diseases. Our clone UP-H2 was validated in the panel for the diagnosis of a subset of acute myeloid leukemias according to Euroflow, a consortium funded by the European Union to define suitable markers for hematopoietic malignancies.
CATALOGUE
CLONE | SPECIFICITY | ISOTYPE |
HP-1F7 | HLA class I | IgG1 |
HP-3D9 | CD94 | IgG1 |
HP-3B1 | CD94 | IgG2b |
HP-3G10 | CD161 | IgG1 |
HP-4B3 | CD69 | IgG1 |
HP-F1 | ILT2 (LIR1, CD85j, LILRB1) | IgG1 |
HP-MA4 | CD158 (KIR2DL1/S1/S3/S5) | IgG2 |
HP-3E4 | CD158 (KIR2DL1/S1/S3/S4/S5) | IgM |
UP-D1 | CD300f (IREM-1) | IgG1 |
UP-D2 | CD300f (IREM-1) | IgG1 |
UP-H1 | CD300e (IREM-2) | IgG2a |
UP-H2 | CD300e (IREM-2) | IgG1 |
UP-R1 | CD158f (KIR2DL5) | IgG1 |
LICENSE CONDITIONS
- Worldwide license
- Non-exclusive license
- An up-front payment
- Royalty on Sales
- Without any right to sublicense
COMMERCIAL OPPORTUNITY
CONTACT
Dr Cinta Diez
Technology Transfer Unit
(+34) 93 316 09 13
[email protected]